Cell-free Enzymatic DNA Synthesis to enable synthetic biology
| Reference number | |
| Coordinator | Moligo Technologies AB |
| Funding from Vinnova | SEK 1 500 000 |
| Project duration | May 2024 - May 2025 |
| Status | Ongoing |
| Venture | Ground-breaking technology solutions |
| Call | Groundbreaking and scalable technology solutions in 2024 |
Purpose and goal
Moligo is a DNA synthesis company producing long single stranded DNA oligonucleotides (ssDNA) with unprecedented purity, length and scale through an enzyme-based proprietary approach. With the support of Vinnova funding, Moligo will develop new DNA based technologies for the synthesis of longer and more complex DNA sequences, enabling the development of new therapeutics and new applications in synthetic biology.
Expected effects and result
The project´s success will be pivotal for expanding our business, freeing us from reliance on other international double-stranded DNA suppliers. This will shorten the development time for our clients to reach clinical trials, where they need 1000 times more of our DNA products. With the implementation of this project, Moligo Technologies will become a key global supplier of high quality synthetic DNA, a partner of choice for the largest biotech and pharma companies.
Planned approach and implementation
Moligo will develop an in-house, fast and cost-effective DNA assembly technology for the synthesis of long, complex double-stranded DNA molecules through the following technical implementation steps: (i) development of a DNA assembly algorithm, (ii) synthesis and assembly of DNA sequences obtained through the algorithm (iii) cloning-free of full and accurate assembly in milligram scale, (iv) in vitro assembly of real case sequences for mRNA production templates and long therapeutic genes for cell and gene therapy.